New pill tested for aggressive brain cancer comeback
NCT ID NCT05023551
Summary
This early-stage study is testing the safety and finding the right dose of an experimental oral drug called DSP-0390 for adults whose aggressive brain tumors (high-grade gliomas) have returned. The main goals are to see what side effects occur and to measure how the drug behaves in the body. Researchers will also check if the treatment shows any early signs of slowing tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Columbia University
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 10032, United States
-
Hokkaido University Hospital
Sapporo, Hokkaido, 060-8648, Japan
-
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, 84112, United States
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Kyoto University Hospital
Kyoto, Sakyo-ku, 606-8507, Japan
-
National Cancer Center Hospital
Chuo Ku, Tokyo, 104-0045, Japan
-
University of California at San Francisco
San Francisco, California, 94143, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.